Anidulafungin is also known by its previous investigational designation, LY303366.
Understanding Anidulafungin's Various Designations
Anidulafungin, a potent antifungal medication, has been identified by several names throughout its lifecycle, from early research to commercial availability. These designations serve distinct purposes, helping to track the compound's development and its market presence.
Previous Investigational Name
During its research and development phase, before receiving its official generic name, Anidulafungin was referred to by a specific code:
- LY303366: This alphanumeric identifier was used to designate the compound while it was undergoing clinical studies and before it was granted its International Nonproprietary Name (INN) of Anidulafungin. Such codes are common in the pharmaceutical industry for tracking experimental drugs.
Common Trade Names (Brand Names)
Once approved for medical use, Anidulafungin is sold under various brand names, which can differ based on geographical regions. These trade names are what patients and healthcare professionals typically encounter in clinical settings:
- Eraxis: This is one of the widely recognized trade names for Anidulafungin.
- Ecalta: Another significant trade name under which Anidulafungin is marketed.
What is Anidulafungin?
Anidulafungin is classified as a semisynthetic echinocandin. It functions as an antifungal drug by targeting and inhibiting the synthesis of a vital component of the fungal cell wall. This mechanism of action makes it effective in treating various serious fungal infections.
Here's a summary of the different ways Anidulafungin is known:
| Type of Name | Specific Name | Description |
|---|---|---|
| Investigational ID | LY303366 | The code used during its research and development. |
| Generic Name (INN) | Anidulafungin | The official, non-proprietary name for the drug. |
| Trade Name | Eraxis | One of the common brand names under which it is sold. |
| Trade Name | Ecalta | Another common brand name for the medication. |
